继乳腺癌产品后，科兴制药布局前列腺癌系列产品线

Group 1 - The core viewpoint of the news is that Kexing Pharmaceutical is making significant progress in overseas commercialization, with multiple product approvals and collaborations announced in December 2025, indicating a strong push into international markets [1] - Kexing Pharmaceutical has entered into a partnership with Jiangxi Kairui Pharmaceutical, a subsidiary of Qingfeng Pharmaceutical Group, to introduce Enzalutamide Soft Capsules in 11 countries and regions, including Brazil, Argentina, and Colombia [1][2] - The collaboration on Enzalutamide Soft Capsules marks the second product partnership between Kexing and Qingfeng, following the earlier agreement on Olaparib tablets in April 2024 [1] Group 2 - Enzalutamide is a drug targeting advanced prostate cancer, particularly for high-risk non-metastatic castration-resistant prostate cancer (NM-CRPC) and symptomatic metastatic castration-resistant prostate cancer (CRPC) patients [2] - In 2022, there were 1.467 million new cases of prostate cancer globally, making it the second most common cancer among men, with incidence rates increasing with age [2] - The global incidence of prostate cancer increased by 42% from 2007 to 2017, with Brazil reporting 62 new cases per 100,000 men [2] Group 3 - Enzalutamide is recognized as a new generation treatment for prostate cancer, with significant efficacy and safety, and it is the most comprehensive androgen receptor inhibitor for prostate cancer indications [3] - The global sales of Enzalutamide exceeded $5 billion in 2023, indicating a substantial market demand [3] - The partnership between Kexing and Qingfeng aims to leverage their strengths for mutual growth and to benefit more patients, enhancing Kexing's product line in oncology [3]